DEF: Silexion Therapeutics Seeks Shareholder Approval for Reverse Stock Split and Expanded Equity Plan Amid Nasdaq Listing Challenges

Silexion Therapeutics Corp. is convening its 2025 annual general meeting to seek shareholder approval for a reverse share split aimed at maintaining Nasdaq listing compliance and an increase in its equity incentive plan to better align employee and director interests.

Summary

• Silexion Therapeutics Corp. will hold its 2025 annual general meeting on July 7, 2025, at 9:00 a.m. Eastern time/4:00 p.m. Israel time, with options for in-person and virtual attendance.
• Shareholders will vote on four key proposals: re-election of seven directors, re-appointment of Kesselman & Kesselman (PwC Israel) as independent auditors for 2025, approval of a reverse share split, and an increase in the 2024 Equity Incentive Plan share pool.
• The proposed reverse share split, at a ratio of not less than 1-for-5 and not more than 1-for-15, is intended to help the company regain and/or maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Silexion previously failed to comply with the minimum bid price rule in October 2024, leading to a 1-for-9 reverse share split in November 2024, which temporarily restored compliance by December 2024; however, the share price has frequently closed below $1.00 since May 6, 2025.
• The company received a delisting notice from Nasdaq on May 22, 2025, due to non-compliance with minimum Market Value of Listed Securities and Market Value of Publicly Held Shares, and has requested a hearing.
• The proposal to increase the 2024 Equity Incentive Plan by 1,271,859 ordinary shares, to a total of 1,428,268 shares (adjusted for any reverse split), aims to address a current shortfall where the total equity pool is less than 1.4% of outstanding share capital, significantly below the 10% recommended by institutional shareholder groups.
• The Board of Directors will also present its annual report on the management of the business for the year ended December 31, 2024, and review the company's consolidated financial statements for the same period.
• As of May 30, 2025, Silexion had 8,692,392 ordinary shares outstanding.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company is actively addressing critical issues like Nasdaq listing compliance and employee incentives, the recurring nature of these problems (e.g., needing a second reverse split, multiple delisting notices) indicates underlying instability in its market valuation and operational funding. The capital raise is a positive, but the ongoing need for financing and the inherent risks of a reverse split temper overall optimism.

Positives

• The company is proactively addressing Nasdaq listing compliance issues through proposed actions like the reverse share split and a hearing request.
• The proposed increase in the equity incentive plan aims to align the interests of employees, officers, and directors with shareholders, which is a critical tool for retention and motivation.
• The Board of Directors is recommending approval of all proposals, indicating unified management support for these strategic initiatives.
• The company successfully completed a public offering in January 2025, raising $5.0 million, demonstrating an ability to secure capital.

Negatives

• Silexion Therapeutics is facing recurring Nasdaq listing compliance issues, including a recent delisting notice for market value deficiencies and a persistent struggle to maintain the $1.00 minimum bid price, necessitating another reverse share split proposal.
• The current equity incentive pool is significantly undersized at less than 1.4% of fully diluted share capital, which is 'far below' the 10% recommended by institutional shareholder groups, potentially hindering the company's ability to attract and retain talent.
• There is no assurance that the proposed reverse share split will proportionally increase the share price or sustain any increase, and it may negatively impact market liquidity and increase price volatility.
• The company acknowledges that if it cannot obtain funding on a timely basis, it may be required to significantly curtail, delay, or discontinue research, development, or manufacturing programs.

Risks

• A reverse share split may not proportionally increase the market price of ordinary shares, or any increase may not be sustained, potentially leading to a greater percentage decline than without the split.
• The reverse share split could negatively impact the liquidity of ordinary shares due to a reduced number of outstanding shares, and may increase the cost of selling shares for holders of odd lots.
• Following a reverse share split, ordinary shares may experience extreme price volatility, low trading volume, and large bid-ask spreads, making it difficult for investors to assess the rapidly changing value.
• Such volatility could adversely affect the company's ability to issue additional ordinary shares or other securities and obtain additional financing, which is a key strategic goal.
• The proposed increase in the 2024 Equity Incentive Plan could result in substantial dilution to existing shareholders if a large number of additional ordinary shares are issued to officers, employees, and directors.
• Resales of ordinary shares issued under the expanded equity plan may cause the trading price of the ordinary shares to decrease, potentially substantially.
• Broad market fluctuations and general economic and political conditions, including those in Israel where operations are centered, may adversely affect the market price of ordinary shares.
• There is no guarantee that the company will successfully appeal the Nasdaq delisting notice or maintain compliance with listing requirements even if the reverse split is successful.

Future Outlook

Silexion Therapeutics expects its research and development expenses to increase substantially as it advances product candidates through clinical studies. The company intends to potentially issue shares through financing arrangements to meet working capital needs and may seek to complete a public offering during the second or third quarters of 2025. The proposed reverse share split is intended to assist in future capital raising efforts by maintaining a share price comfortably above the Nasdaq minimum bid price.

Management Comments

• The Board believes the current directors 'have successfully guided the Company throughout this potentially difficult initial period' since the Business Combination.
• The Board states that the current directors 'deeply understand the Company, its product candidates and the Israeli biotech industry in which the Company operates, and who can therefore be relied upon to navigate the Company for the next year.'
• Management views the reverse share split as 'in our best interest strategically, as it will assist us in raising capital to continue to support our preclinical studies and clinical trials.'
• The Board is 'committed to maintaining our conformity to the 10% limit that is favored by institutional shareholder groups' for the total equity incentive pool.

Industry Context

Silexion Therapeutics operates within the Israeli biotech industry, a sector characterized by high research and development costs and a reliance on capital markets for funding. The company's challenges with Nasdaq listing compliance, particularly the minimum bid price and market value requirements, are common for smaller-capitalization and relatively new public companies, especially those in volatile sectors like biotechnology. The emphasis on equity incentives aligns with industry standards for attracting and retaining talent in competitive R&D-intensive fields, where aligning employee interests with shareholder value is crucial. The document also notes a broader market trend of 'extreme share price run-ups followed by rapid price declines and strong share price volatility' affecting smaller public floats.

Comparison to Industry Standards

• The company's current equity incentive pool, at less than 1.4% of its fully diluted share capital, is 'far below the recommended limit of 10% espoused by institutional shareholder groups,' indicating a significant deviation from common industry practice for incentivizing employees and directors.
• Kesselman & Kesselman (PwC Israel) is highlighted as a 'major participant in the Israeli high-tech and health sciences worlds, serving as independent auditor to many other U.S.-listed Israeli medical device and pharmaceutical companies,' suggesting their re-appointment aligns with industry-recognized auditing standards and expertise for similar companies.

Management Changes

Corporate Governance

Legal Proceedings

• To the knowledge of management, there is no material litigation, arbitration, or governmental proceeding currently pending against the company or any members of its management team in their capacity as such.

Related Party Transactions

• Ilan Hadar (CEO & Chairman) and Mirit Horenshtein Hadar (CFO & Secretary) are spouses, and their employment agreements constitute related party transactions.
• Guangzhou Sino-Israel Bio-Industry Investment Fund I (GIBF), which beneficially owned 20.3% of shares post-Business Combination, exchanged its 49% interest in the Chinese subsidiary for 203,971 ordinary shares and an additional 16,817 shares for services. Directors Avner Lushi and Shlomo Noy share voting and investment power over GIBF's shares.
• A PIPE Financing of $2.0 million was conducted with Greenstar, LP, an affiliate of the Moringa sponsor, immediately prior to the Business Combination.
• An Amended and Restated Sponsor Promissory Note for $3,433,000 was issued to Moringa's sponsor, with amounts convertible into ordinary shares.
• An Amended and Restated Registration Rights and Lock-Up Agreement was entered into with Moringa's sponsor, distributees, pre-Business Combination shareholders, the PIPE Investor, and EarlyBirdCapital, Inc., granting registration rights (lock-up periods have expired).

Stakeholder Impact

• Shareholders face potential dilution from the proposed increase in the equity incentive plan and the uncertainty of the reverse share split's impact on share price and liquidity, alongside the risk of Nasdaq delisting.
• Employees, officers, and directors are directly impacted by the proposed increase in the equity incentive plan, which aims to provide sufficient equity compensation to align their interests with shareholder value and enhance retention.
• Potential investors and financing sources may be deterred by the company's low share price and recurring Nasdaq listing issues, which could impede future capital raising efforts.
• Nasdaq's reputation and listing standards are maintained through the company's efforts to comply with minimum bid price and market value rules, with a hearing requested to address current deficiencies.
• Creditors and suppliers may be indirectly impacted by the company's financial health and ability to raise capital, which is crucial for funding its expensive preclinical studies and clinical trials.

Next Steps

• Shareholders are urged to promptly vote on the proposals for the annual general meeting by July 4, 2025.
• The Board of Directors will determine the exact reverse share split ratio (between 1-for-5 and 1-for-15) prior to the annual general meeting.
• A Nasdaq panel hearing is expected in late June 2025 to address the delisting notice received on May 22, 2025.
• The Board will present its annual report on the management of the business for the year ended December 31, 2024, and review the company's consolidated financial statements for 2024 at the annual general meeting.
• The company may seek to complete a public offering during the second or third quarters of 2025 to support working capital needs and preclinical/clinical development.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, SEC Filing, Proxy Statement, Annual General Meeting, Reverse Stock Split, Nasdaq Listing Compliance, Equity Incentive Plan, Corporate Governance, Biotechnology, Pharmaceutical, Israel, Shareholder Vote, Capital Raise